Clinical Trial Update: Obinutuzumab in Primary FSGS [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating obinutuzumab for primary focal segmental glomerulosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Primary Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED